A Closer Look At Nuclear Medical Imaging

Volume 17 - Issue 9 - September 2004
9514 reads
0 comments

Start Page: 36

The combination of the two studies (with the Indium-WBC study on the left and the 99m Tc-MDP study on the right) delineates the region of an infectious process within the cuboid bone while simultaneously ruling out the existence of infection elsewhere wit

This photo demonstrates an area of ulceration with localized erythema, warmth and edema three years after an acute Charcot breakdown.

This lateral radiograph shows the end result of a neuropathic breakdown: a rocker bottom foot with a plantarflexed cuboid bone creating a pressure point and ulceration.

As one can see, the 99mTc-MDP study reveals the extent of degenerative bone in a “burned out” Charcot foot while the indium 24-hour image fails to reveal a focus of infection in that same patient with Charcot neuroarthropathy.

One can employ serial NMLI studies initially to identify the extent of an infectious process and subsequently to confirm therapeutic success. The initial 99mTc-MDP study reveals a focus of uptake that seems to include the head of the first metatarsophalan

Author(s):

By Molly S. Judge, DPM, CNMT, and Nellie L. Kelty, MAS, CNMT

4. Preston DF: Indium-111 Label in Inflammation and Neoplasm Imaging Ch.29 In Principals and Practice of Nuclear Medicine 2nd ed, pp.714-724, edited by PJ Early and DB Sodee, Mosby, St Louis, 1995.

5. McAfee, JG, Thakur ML: Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. 1. Soluble agent. J Nuc Med 17:480-487, 1976.

6. McAfee, JG, Thakur ML: Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. 2. Particles. J Nuc Med 17:488-492, 1976.

7. Schauwecker DS, Park HM, Burt RW, Mock BH and Wellman HN: Combined bone scintography and indium-111 leukocyte scans in neurotrophic foot disease. J Nuc Med 29(10): 1651-1655, 1988.

8. Datz FL, Thorne DA: Effect of chronicity of infection on the sensitivity of the In-111-labeled leukocyte scan. AJR 147:809-812, 1986.

9. Keenan AM, Tindel NL and Alavi A: Diagnosis of pedal osteomyelitis in diabetic patients using current scintigraphic techniques. Arch Int Med 149:22622266,1989.

10. Nepola JV, Seabold JE, Marsh JL et al: Diagnosis of infection in ununited fractures. JBJS 75(12):1816-1822, 1993.

11. Seabold JE, Flickinger FW, Kao SC, Gleason TJ et al: Indium- ¹¹¹-leukocyte/technetium-99m-MDP bone and magnetic imaging: Difficulty in diagnosing osteomyelitis in patients with neuropathic osteoarthropathy. J Nuc Med 31:549-556, 1990.

12. Palestro CJ, Kim CK, Swyer AJ et al: Total-hip arthroplasty: Periprosthetic indium-111-labeled leukocyte activity and complementary technetium-99m-sulfur colloid imaging in suspected infection. J Nuc Med 31(12):1950, 1990.

13. Seabold JE, Forstrom LA, Schauwecker DS et al: Procedure guideline for indium-111-leukocyte scintigraphy for suspected infection/inflammation. J Nuc Med 38:997-1001, 1997.

14. Larcos G, Brown ML and Sutton RT: Diagnosis of osteomyelitis of the foot in diabetic patients: Value of In-111-leukocyte scintigraphy. AJR 157:527-531, 1991.

15. Palestro CJ, Mehta HH, Patel M et al: Marrow versus infection in the Charcot joint: Indium-111 leukocyte and technetium-99m sulfur colloid scintigraphy. J Nuc Med 39(2):346-350, 1998.

16. Magnuson JE, Brown M, Hauser MF et al: In-111-labeled leukocyte scintography in suspected orthopedic prosthesis infection: comparison with other imaging modalities. Rad 168:235-239, 1988.

17. McAffe JG, Gagne G, Subramanian G et al: The localization of indium-111-leukocytes, Gallium-67-polyclonal IgG and other radioactive agents in acute focal inflammatory lesions. J Nuc Med 32(11):2126-2131, 1991.

18. Baldwin JE and Wraight EP: Indium labeleld leukocyte scintography in occult infection: A comparison with ultrasound and computed tomography. Clin Rad 42: 199-202, 1990.

19. Peters AM: The utility of (^99mTc) HMPAO-leukocytes for imaging infection. Seminars Nuc Med 24(2):10-127, 1994.

20. Kao CH, Huang WT, Wang YL et al: A comparative study of ^99mTc-HMPAO and ^99mTc-ECD as a leukocyte-labeling agent. Nuc Med Communications 15:294-297, 1994.

21. Hovi I: Complicated bone and soft tissue infections, imaging with 0.1T MR and ^99mTc-HMPAO-labeled leukocytes. Acta Rad 37:870-876, 1996.

22. Datz FL, Seabold JE, Brown ML et al: Procedure guideline for technetium-99m-HMPAO-labeled leukocyte scintigraphy for suspected infection/inflammation. J Nuc Med 38(6): 987-990, 1997.

23. Devillers A, Moisan A, Hennion F et al: Contribution of technetium-99m hexamethylpropylene amine oxime labeled leukocyte scintigraphy to the diagnosis of diabetic foot infections. Eur J Nuc Med 25(2):132-138, 1998.

24. Shih WJ, Han JK, Magoun S et al: Detection of abscesses with Tc-99m HMPAO leukocyte scintigraphy depends on their stage and location. Clin Nuc Med 24(2):111-114, 1999.

25. Roca M, Martin-Comin J, Becker W et al: A consensus protocol for white blood cells labeling with technetium-99m hexamethylpropylene amine oxime. Eur J Nuc Med 25(7): 797-799, 1998.

26. Reynolds JH, Graham D and Smith FW: Imaging Inflammation with ^99mTc-HMPAO Labeled leucocytes. Clinical Radiology 42:195-198, 1990.